![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Antiepileptic drugs (AEDs) are currently used in both neurology and in psychiatry. It is generally accepted that GABA-ergic compounds have sedative and anxiolytic properties, whereas channel blockers are mood stabilizers. However, this paradigm is often challenged. This is related to the variety of mechanisms of action of individual AEDs on biological systems, only some of which are related to the desired CNS effect. At present, just a few AEDs are licensed for psychiatric indications, namely carbamazepine, valproate, lamotrigine and pregabalin. Data on other AEDs show potential benefits, but are still inconclusive in some cases. This article discusses molecular targets of AEDs relevant for their psychotropic properties with special attention to newest compounds. Current knowledge gaps are also highlighted.
Financial & competing interests disclosure
The author has received no compensation for the present paper but has received, in the past, travel grants or consultancy fees from various pharmaceutical companies including Pfizer, UCB Pharma and Janssen, which are involved in the manufacture of antiepileptic drugs. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.